Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAN1012 + Toripalimab in Advanced Solid Tumors
NCT06410703Phase 2Recruiting
- Sponsor
- Canwell Biotech Ltd.
- Start
- Jun 2024
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of CAN1012 in solid tumor (advanced stage), sponsored by Canwell Biotech Ltd.. Started Jun 2024; status: recruiting.
02
Drugs
CAN1012
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06410703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06410703.